BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.
The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.
BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.
The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.
BlinkLab's shares fell past 2% in recent Tuesday trade.